IKIDO
IKIDO50About
What does IKIDO do?
IKIDO provides an adaptive, real-time bill of materials (BOM) optimization platform. It helps companies navigate supply chain challenges by identifying risks, suggesting alternatives, and optimizing sourcing for electronic components throughout the product lifecycle, from initial design onwards.
What is IKIDO's revenue?
StartupHub estimates IKIDO's annual revenue at $3.1M (range $1.7M to $4.2M, 64% confidence), based on comparable companies in the sector.
What is IKIDO's valuation?
StartupHub estimates IKIDO's effective valuation at $88.0M (range $55.0M to $132.0M, 10% confidence), based on comparable companies in the sector.
How much funding has IKIDO raised?
IKIDO has raised a total of $22M in funding. The most recent round on record is Seed.
Where is IKIDO headquartered?
IKIDO is headquartered in Tel Aviv, Israel.
When was IKIDO founded?
IKIDO was founded in 2020.
What industry does IKIDO operate in?
IKIDO operates in Industrial, Manufacturing, Supply Chain, Electronics, Industrial Manufacturing, Electronic Components.
How many employees does IKIDO have?
IKIDO has approximately 6 people on record.
Designs, manufactures, and markets medical devices for diabetes care, wound care, and drug delivery.
Provides insights and strategies for cost-effective engineering solutions.
Get your production line back online in minutes with an industrial troubleshooting platform that captures and organizes institutional knowledge.
AI diagnostics for stamping and metal-forming technicians, grounded in your own manuals.
Manufacturer and distributor of bathroom furniture, operating in Europe, USA, South America, and Africa.
Manufacturer, packager, and distributor of private-label over-the-counter pharmaceutical and consumer healthcare products.
An entrant is a company tagged Manufacturing whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.